Nadir CA-125 has prognostic value for recurrence, but not for survival in patients with ovarian cancer.
Journal
Scientific reports
ISSN: 2045-2322
Titre abrégé: Sci Rep
Pays: England
ID NLM: 101563288
Informations de publication
Date de publication:
14 09 2021
14 09 2021
Historique:
received:
27
12
2020
accepted:
20
08
2021
entrez:
15
9
2021
pubmed:
16
9
2021
medline:
15
12
2021
Statut:
epublish
Résumé
The objective of this study was to evaluate the nadir CA-125 in patients with epithelial ovarian cancer. A total of 168 patients who achieved complete remission (no clinical and radiological signs, CA-125 ≤ 35 U/ml) after first-line treatment were enrolled in the study. The relationship between CA-125 and survival was examined by applying generalized additive models to the Cox proportional hazards model. The median CA-125 concentration after the treatment was 10 U/ml (2.7-35 U/ml). The nadir CA-125 was related to progression-free survival but not to overall survival. The risk of recurrence in patients with 11-25 U/ml and 26-35 U/ml compared to patients with ≤ 10 U/ml was 1.87 (p < 0.0024) and 2.17 (p < 0.018), respectively. An increased risk of recurrence according to the nadir CA-125 (≤ 10 U/ml vs. 11-25 U/ml and ≤ 10 U/ml vs. 26-35 U/ml) was found in patients with high-grade tumours (hazard ratio, HR = 2.08 and 2.59, respectively), advanced disease (HR = 2.38 and 2.03, respectively), serous histology (HR = 2.08 and 2.43, respectively) and after complete cytoreduction (HR = 2.7 and 2.72, respectively). No correlation between the CA-125 nadir and recurrence risk was found in patients with early-stage disease or those receiving neoadjuvant chemotherapy or bevacizumab.
Identifiants
pubmed: 34521891
doi: 10.1038/s41598-021-97564-1
pii: 10.1038/s41598-021-97564-1
pmc: PMC8440776
doi:
Substances chimiques
CA-125 Antigen
0
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
18190Informations de copyright
© 2021. The Author(s).
Références
Acta Obstet Gynecol Scand. 2020 Jul;99(7):933-940
pubmed: 31954071
Ann Oncol. 2008 Feb;19(2):327-31
pubmed: 18065408
J Surg Oncol. 2009 Sep 1;100(3):244-7
pubmed: 19267361
J Cancer. 2016 Nov 25;7(15):2327-2332
pubmed: 27994671
Cancer. 2009 Mar 1;115(5):1028-35
pubmed: 19156927
J Oncol. 2010;2010:497429
pubmed: 20066162
J Gynecol Oncol. 2008 Sep;19(3):169-72
pubmed: 19471573
Gynecol Oncol. 2020 Mar;156(3):689-694
pubmed: 31889528
Am J Obstet Gynecol. 1989 Mar;160(3):667-71
pubmed: 2648838
Gynecol Oncol. 2010 Nov;119(2):265-9
pubmed: 20797777
Gynecol Oncol. 2007 Jan;104(1):176-80
pubmed: 16996584
J Ovarian Res. 2020 Sep 2;13(1):102
pubmed: 32878632
Cancer. 2008 Apr 15;112(8):1726-32
pubmed: 18300236
J Cancer. 2017 Sep 20;8(17):3410-3415
pubmed: 29151924
J Clin Oncol. 2006 Mar 20;24(9):1454-8
pubmed: 16549840
Gynecol Oncol. 1992 Jul;46(1):29-32
pubmed: 1634137
Mol Clin Oncol. 2021 Jan;14(1):8
pubmed: 33262888
Hum Reprod. 1989 Jan;4(1):1-12
pubmed: 2651469
Gynecol Oncol. 2009 Nov;115(2):209-14
pubmed: 19664812
Gynecol Oncol. 1995 Nov;59(2):251-4
pubmed: 7590482
Anticancer Res. 2015 Feb;35(2):1099-104
pubmed: 25667499
J Ovarian Res. 2013 Apr 25;6:31
pubmed: 23618037
Int J Gynecol Cancer. 2009 Apr;19(3):367-74
pubmed: 19407561
Int J Gynecol Cancer. 1997 Jan;7(1):42-5
pubmed: 12795803
Scand J Clin Lab Invest. 2000 Dec;60(8):713-21
pubmed: 11218154
Ann Oncol. 2006 Aug;17(8):1234-8
pubmed: 16766592